Edgewise Therapeutics Inc (EWTX) Stock Analysis
Verdict: HOLD
Pipeline momentum and high analyst conviction drive price toward $51, but aggressive insider selling and zero revenue mandate caution.
Investment score: 64/100
Analysis as of
Is Edgewise Therapeutics Inc stock worth reviewing? The TradeMates thesis
EWTX shows strong clinical-stage momentum with institutional backing, but high valuation and insider exits indicate a balanced risk/reward near current levels.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 80/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Edgewise Therapeutics Inc opportunities and risks
What speaks for EWTX
- Clinical Milestone Advancement
What speaks against EWTX
- Binary Clinical Success Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| EWTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.1% |
| DFTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.9% |
| AMRX | 44.8x | 1.8x | 12.7x | 38.7% | 4.0% | 3.8% |
| INDV | 20.1x | 3.9x | 15.3x | 83.1% | 19.4% | -3.7% |
| MANE | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.9% |
| GPCR | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.2% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.9% |
Frequently asked questions about Edgewise Therapeutics Inc (EWTX)
Is EWTX stock a good investment?
The TradeMates model rates Edgewise Therapeutics Inc as HOLD with an investment score of 64/100. EWTX shows strong clinical-stage momentum with institutional backing, but high valuation and insider exits indicate a balanced risk/reward near current levels. This is algorithmic model output, not personal investment advice.
Is EWTX stock a buy?
The TradeMates model verdict for EWTX is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.